No CrossRef data available.
Article contents
The treatment of anxiety disorders: a legacy of William Sargant*
Published online by Cambridge University Press: 16 April 2020
Summary
In 1962 William Sargant and his colleagues described the therapeutic value of phenelzine, a monoamine oxidase inhibitor (MAOI), in chronic anxiety disorders and in the same year Klein and Fink reported the treatment of similar conditions with imipramine, a tricyclic antidepressant. Subsequent research has confirmed these findings and demonstrated the range of similar drugs that are effective in anxiety disorders. At the time of these original observations about the drug treatment of anxiety, there were no psychological treatments of proven value but in the intervening years much progress has been made in developing behavioural and cognitive procedures. The progress in determining the mode of action of these pharmacological and psychological treatments is reviewed and the implications of the findings are considered in relation to research into the causes of the anxiety disorders and to the treatment of patients.
- Type
- Original article
- Information
- Copyright
- Copyright © European Psychiatric Association 1997
References
Andersch, SRosenberg, NKKullingsjo, HOttosson, J-OBech, PBruunberg, REfficacy safety of alprazolam imipra-mine and placebo in treating panic disorder. A Scandinavian multicenter study Acta Psychiatr Scand 365(suppl) 1991 18–27CrossRefGoogle ScholarPubMed
Angst, JDobler-Mikola, ABinder, JThe Zurich Study: a prospective epidemiological study of depressive neurotic and psychosomatic syndromes Eur Arch Psychiatry Neurol Sci 234 1984 13–20CrossRefGoogle ScholarPubMed
Arntz, Avan den Hout, MPsychological treatments of panic disorder without agoraphobia: cognitive therapy versus applied relaxation Behav Res Ther 34 1996 113–121CrossRefGoogle ScholarPubMed
Beaudry, PFontaine, DChouinard, G, et al.Bromazepam, another high potency benzodiazepine for panic attacks Am J Psychiatry 141 1984 464–465Google ScholarPubMed
Beck, ATLaude, RBohnerational components of anxiety neurosis Arch Gen Psychiatry 31 1974 319–325CrossRefGoogle ScholarPubMed
Beck, ATSokol, LClark, DABerchick, BWright, FFocused cognitive therapy for panic disorder: a crossover design and one year follow-up Am J Psychiatry 147 1992 778–783Google Scholar
Black, DWWesner, RBowers, WGabel, JA comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder Arch Gen Psychiatry 50 1993 44–50CrossRefGoogle ScholarPubMed
Bradwejn, JKoszycki, DCouetoux du Tertre, Avan Megen, MDden Boer, JWestenberg, HAnnable, LThe panicogenic effects of choleocystokinin tetrapeptide are antagonized by L-365,260, a central choleocystokinin receptor antagonist, in patients with panic disorder Arch Gen Psychiatry 51 1994 486–493CrossRefGoogle Scholar
Butler, GFennell, MJVRobson, PGelder, MGComparison of behaviour therapy and cognitive behaviour therapy in the treatment of generalized anxiety disorder 7 Consult Clin Psychol 59 1991 167–175CrossRefGoogle Scholar
Cassano, GBPetracca, APergugi, G, et al.Clomipramine for panic disorder: I The first 10 weeks of a long-term comparison with imipramine J Affect Disord 14 1988 123–127CrossRefGoogle ScholarPubMed
Charney, DSHeninger, GRBreier, ANoradrenergic function in panic anxiety Arch Gen Psychiatry 41 1984 751–783CrossRefGoogle ScholarPubMed
Charney, DSWoods, SWGoodman, WK, et al.Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone J Clin Psychiatry 47 1986 580–586Google ScholarPubMed
Charney, DSWoods, SWBenzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam J Clin Psychiatry 50 1989 418–423Google ScholarPubMed
Clark, DMSalkovskis, PMHackmann, AMiddleton, HAnas-tasiades, PGelder, MGA comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder Br J Psychiatry 164 1994 759–769CrossRefGoogle ScholarPubMed
Clark, DMWells, AA cognitive model of social phobia In: Heimberg, RLiebowitz, MHope, DASchneier, FR eds.Social phobia: diagnosis, assessment and treatment 1995 Guilford Press New YorkGoogle Scholar
Cross-National Collaborative Panic Study Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo Br J Psychiatry 160 1992 191–202CrossRefGoogle Scholar
Deakin, JWGraeff, Psychology, 5-HT and mechanisms of defence J Psychopharmacol 5 1991 305–315CrossRefGoogle Scholar
den Boer, JAWestenberg, HGMEffects of a serotonin uptake inhibitor in panic disorder: a double blind comparative study with fluvoxamine and maprotiline Int J Clin Psycho-pharmacol 3 1988 59–74CrossRefGoogle ScholarPubMed
Dunner, DLIshiki, DAvery, DH, et al.Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study J Clin Psychiatry 47 1986 458–460Google ScholarPubMed
Durham, RMurphy, TAllan, TRichard, KTreliving, LRCognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder Br J Psychiatry 165 1994 315–323CrossRefGoogle Scholar
Durham, RCTurvey, AACognitive therapy vs behaviour therapy in the treatment of chronic generalized anxiety Behav Res Ther 25 1987 229–334CrossRefGoogle Scholar
Fahy, TJO'Rourke, DBrophy, JSchazmann, WSciascia, SThe Galway study of panic disorder.I Clomipramine and lofepramine in DSM III-R panic disorder: a placebo con-trolled trial J Affect Disord 25 1992 63–76CrossRefGoogle Scholar
Fyer, AJMannuzza, SChapman, TFMartin, LYKlein, DFSpecificity in familial aggregation of phobic disorders Arch Gen Psychiatry 52 1995 564–573CrossRefGoogle ScholarPubMed
Gelernter, CSUhde, TWCimbolic, PArnkoff, DBVittone, BJTancer, MEBartko, JJCognitive-behavioural and pharmacological treatment of social phobia Arch Gen Psychiatry 48 1991 938–945CrossRefGoogle Scholar
Gentil, VLotufo-Neto, FAndrade, LCordas, TBernik, MRamos, R, et al.Clomipramine a better reference drug for panic/agoraphobia. I Effectiveness comparison with imipramine J Psychopharmacol 7 1993 316–324CrossRefGoogle ScholarPubMed
Gorman, JMAskanazi, JLiebowitz, MRFyer, AJStein, JKinney, JMKlein, DFResponse to hyperventilation in a group of patients with panic disorder Am J Psychiatry 141 1984 857–861Google Scholar
Gorman, JMLiebowitz, MRFyer, AJGoetz, DCampeas, RBFyer, MR, et al.An open trial of fluoxetine in the treatment of panic attacks J Clin Psychopharmacol 7 1987 329–332CrossRefGoogle ScholarPubMed
Hoehn-Saric, RMcLeod, DRZimmerlin, WDDifferential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms J Clin Psychiatry 49 1988 293–301Google ScholarPubMed
Kahn, RJMcNair, DMLipman, RSCovi, LRickeis, KDowning, R, et al.Imipramine and chlordiazepoxide in depressive and anxiety disorders: II efficacy in anxious outpatients Arch Gen Psychiatry 43 1986 79–85CrossRefGoogle ScholarPubMed
Katzelnick, DJKobak, KAGreist, JHJefferson, JWMantle, JMSerlin, RCSertraline for social phobia: a double blind placebo controlled crossover study Am J Psychiatry 152 1995 1368–1371Google ScholarPubMed
Kendler, KNeale, MKessler, R, et al.Generalized anxiety disorder in women: a population based twin study Arch Gen Psychiatry 49 1992 267–272CrossRefGoogle ScholarPubMed
Klein, DFFink, MPsychiatric reaction patterns to imipramine Am J Psychiatry 119 1962 432–438CrossRefGoogle ScholarPubMed
Klerman, GLOverview of the cross-national collaborative panic study Arch Gen Psychiatry 45 1988 407–412CrossRefGoogle ScholarPubMed
Liebowitz, MRFyer, AJGorman, JMDillon, DDavies, SStein, JM, et al.Specificity of lactate infusions in social phobia versus panic disorders Am J Psychiatry 142 1985 947–950Google ScholarPubMed
Liebowitz, MRSchneier, FCampeas, RHollander, EHatterer, JFyer, A, et al.Phenelzine vs atenolol in social phobia.A placebo controlled comparison Arch Gen Psychiatry 49 1992 290–300CrossRefGoogle ScholarPubMed
Margraf, JSchneider, SOutcome and active ingredients of cognitive behavioural treatments for panic disorder Paper present at the Annual Conference of Association for Advancement of Behaviour Therapy New York 1991Google Scholar
Marks, IMGelder, MGDifferent ages of onset of varieties of phobia Br J Psychiatry 123 1966 218–221Google ScholarPubMed
Noyes, R JrAnderson, DJClancy, J, et al.Diazepam and propa-nolol in panic disorder and agoraphobia Arch Gen Psychiatry 41 1984 287–292CrossRefGoogle ScholarPubMed
Nutt, DJGlue, PLawson, CWilson, SFlumazenil provocation of panic attacks Arch Gen Psychiatry 47 1990 917–925CrossRefGoogle ScholarPubMed
Ottaviani, RBeck, ATCognitive aspects of panic disorders J Anxiety Disord 1 1987 15–28CrossRefGoogle Scholar
Öst, LGWestling, BApplied relaxation vs cognitive therapy in the treatment of panic disorder Behav Res Ther 33 1995 145–158CrossRefGoogle ScholarPubMed
Pitts, FNMcClure, JNLactate metabolism in anxiety neurosis New Engl J Med 277 1967 1328–1336CrossRefGoogle ScholarPubMed
Power, KGJerrom, DWASimpson, RJMitchell, MJSwanson, VA controlled comparison of cognitive-behaviour therapy, diazepam and placebo in the management of generalised anxiety disorder Behav Psychother 17 1989 1–14CrossRefGoogle Scholar
Power, KGSimpson, RJSwanson, VWallace, LAFeistner, ATCSharp, DA controlled comparison of cognitive behaviour therapy, diazepam, and placebo, alone and in combination for the treatment of generalized anxiety disorder J Anxiety Disord 4 1990 267–293CrossRefGoogle Scholar
Rapee, RMattick, RMurrell, ECognitive mediation in the affective component of spontaneous panic attacks J Behav Ther Exp Psychiatry 17 1986 245–253CrossRefGoogle ScholarPubMed
Rickels, KDowning, RSchweizer, EHassman, HAntidepressants for the treatment of generalized anxiety disorder Arch Gen Psychiatry 50 1993 884–895CrossRefGoogle ScholarPubMed
Sargant, WDally, PTreatment of anxiety states by antidepress-ant drugs Br Med J 1 1962 6–9CrossRefGoogle ScholarPubMed
Sargant, WAim and method in treatment: twenty years of British and American psychiatry J Ment Sci 103 1957 699–709CrossRefGoogle ScholarPubMed
Schweizer, ERickels, KWeiss, SZavodnick, SMaintenance drug treatment of panic disorder Arch Gen Psychiatry 50 1993 51–60CrossRefGoogle ScholarPubMed
Sheehan, DVBallenger, JJacobsen, GTreatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms Arch Gen Psychiatry 37 1980 51–59CrossRefGoogle ScholarPubMed
Tesar, GERosenbaum, JFPollack, MH, et al.Clonazepam vs alprazolam in the treatment of panic disorder: interim analysis of data from a prospective double-blind placebo-controlled trial J Clin Psychiatry 48suppl 111984 16–19Google Scholar
Van der Molen, GMvan den Hout, MAVroemen, JLousberg, HGriez, ECognitive determinants of lactate-induced anxiety Behav Res Ther 24 1986 677–680CrossRefGoogle ScholarPubMed
van, Vliet IMden Boer, JAWestenberg, HGMPsychopharma-cological treatment of social phobia: a double blind placebo controlled study with fluvoxamine Psychopharmacology 115 1994 128–134Google Scholar
Versiani, MNardi, AEMundim, FDAlves, ABLiebowitz, MRAmrein, RPharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine Br J Psychiatry 161 1992 353–360CrossRefGoogle ScholarPubMed
Woods, SWCharney, DSGoodman, WKHeninger, GRCarbon dioxide-induced anxiety Arch Gen Psychiatry 45 1988 43–52CrossRefGoogle ScholarPubMed
Zitrin, CMKlein, DFWoerner, MG, et al.Treatment of phobias I: Comparison of imipramine hydrochloride and placebo Arch Gen Psychiatry 40 1983 125–138CrossRefGoogle ScholarPubMed
Comments
No Comments have been published for this article.